Search

The purpose of the article is to demonstrate the program of the pilot distance course «Fundamentals of the methodology of the development of the electronic course in the field of medical education » to improve the qualifications of teachers of higher medical educational institutions in the use of information and educational web technologies, taking into account modern trends in the development of education and health needs. Methods for assessing the effectiveness of training – questionnaires before and after the training course, the number of electronic courses in the distance-learning platform. As a result of training in the course, the creation of 646 electronic training courses in department categories was started with the placement of methodological information for students in them. According to the survey of 109 teachers, the majority of respondents - 108 teachers (99.08%) confirmed that it was convenient for them to work in the electronic course; the majority of teachers – 108 teachers (99.08%) confirmed that they were disciplined by the need to submit work for verification in each topic of the e-learning course; most of the teachers 97 (88.99%) who were trained in the course were able to immediately implement the acquired knowledge into everyday pedagogical work; the majority of teachers who completed training in the course assessed their level of knowledge on the methodology for the development of electronic courses in the field of medical education «Good» – 62 (56.88%), 37 teachers – «Excellent» (33.94%). The experience of conducting professional development training in the field of medical education can become the basis for the implementation of the national strategy of continuous medical education, the creation of high-quality educational content, both for undergraduate and postgraduate stages of training.

The tyrosine kinase inhibitor (TKI) imatinib in rare cases can cause acute toxic hepatitis, hepatic failure, and death. Currently, the choice of further chronic myeloid leukemia (CML) therapy in patients after acute hepatotoxicity is still a difficult question, which requires a complex individual approach based on the clinical guidelines of adverse event management. Data about the further follow-up strategy approach in patients with CML after acute toxic imatinib-induced liver injury are of concern, and at times controversial. In addition, one of the questions is about the necessity and safety of the imatinib therapy resumption after acute hepatotoxicity. In some publications, imatinib resumption without the recurrence of hepatotoxicity has been discussed; in others, imatinib resumption with the recurrence of imatinib hepatotoxicity has been mentioned. There are a few publications about the experience of administration of the second-line TKIs after acute imatinib hepatotoxicity. There are no clear data on which factors the physician's decision should be based on in patients with CML after acute toxic imatinib-induced liver injury. Imatinib should be restarted or withdrawn, when and for whom second-line therapy should be started. The physician's decision is usually based on the published data of similar cases, personal experience, and the severity of hepatotoxicity. We have discussed the clinical guidelines devoted to the peculiarities of the patient's management after acute toxic imatinib-induced hepatitis and main strategy approaches. A complex score-based decision algorithm for choosing the further strategy approach after acute toxic imatinib-induced hepatitis in patients with CML has been presented. The following parameters should be assessed: the grade of hepatotoxicity reaction, the presence of liver transplantation or imatinib-induced liver cirrhosis and its possible pathogenetic mechanism, the presence of early molecular response (EMR) to imatinib therapy defined as three-month BCR-ABL1 ≤10% according to the international scale (BCR-ABL1IS ) or/and six-month BCR-ABL1 IS

The introduction of imatinib has substantially changed the approaches to the therapy of chronic myeloid leukemia. However, this drug can cause hepatic failure and death in rare cases. This report describes a clinical case of acute, toxic imatinib-induced hepatitis in a 56-year-old woman with chronic myeloid leukemia and concomitant sulfa allergy and rheumatoid arthritis. The patient developed acute imatinib-induced hepatitis after three months of treatment with imatinib and three days after increasing the imatinib dosage from 400 mg per day to 600 mg per day, resolving within three months after imatinib discontinuation and prednisolone administration. This confirms the necessity of great caution during imatinib therapy and the monitoring of liver tests. Approximately 25 reports about clinical cases of imatinib-induced hepatitis have been published up to the present.